Alnylam Pharmaceuticals, Inc (ALNY)

Over the past six months, Alnylam's stock (ALNY) has experienced several notable events and fluctuations. As of January 2, 2026, the stock price was $400.17 per share, a 71.64% increase from January 6, 2025. Key events impacting the stock include robust Q2 and Q3 2025 financial results, concerns about a slowdown in Amvuttra commercialization, analyst ratings adjustments, insider trading with 176 sales of ALNY stock, and lobbying disclosure of $70,000 related to Medicare, Medicaid, and specific acts.

While there is no strong, inherent seasonality in the demand for Alnylam's products, seasonality potentially explains a slowdown in the commercialization of Amvuttra for ATTR-CM in late 2025. The company's revenue growth has been robust across quarters, suggesting that any seasonality might be minor or specific to certain product launches or market dynamics rather than a broad trend.

Alnylam Pharmaceuticals, Inc. specializes in RNAi therapeutics, using small interfering RNA (siRNA) molecules to selectively prevent specific proteins from being made, treating diseases at their genetic root. The company's marketed RNAi therapies include AMVUTTRA (vutrisiran) for hATTR amyloidosis with polyneuropathy and ATTR amyloidosis with cardiomyopathy, ONPATTRO (patisiran) for the polyneuropathy of hATTR amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1), and Leqvio (inclisiran) for hypercholesterolemia. Alnylam maintains a pipeline of investigational RNAi therapeutics targeting rare and prevalent diseases across Genetic Medicines, Cardio-Metabolic Disease, Infectious Disease, and CNS/Ocular Diseases. Key pipeline candidates in late-stage development include vutrisiran, patisiran, lumasiran and fitusiran.

Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, U.S., with large-scale manufacturing facilities in Cambridge and Norton, Massachusetts. Globally, Alnylam has European business offices in Maidenhead, UK, and Zug, Switzerland, and satellite offices in Munich, Germany; Amsterdam, Netherlands; Vienna, Austria; Paris, France; Milan, Italy; Madrid, Spain; and Stockholm, Sweden. Other global offices are located in Tokyo, Japan; Sao Paulo, Brazil; and Mississauga, Ontario, Canada. The company operates subsidiaries across North America, Europe, and Asia-Pacific, with a growing global presence that also extends to South America.

Alnylam Pharmaceuticals has a strong brand reputation as a pioneer and leader in RNAi therapeutics. The company was founded on Nobel Prize-winning science and has consistently advanced RNAi therapeutics from scientific discovery to commercialized products. Alnylam was recognized on Forbes' "100 Most Innovative Growth Companies" list in 2016 and was named a "Best Workplace for Innovators." The company's commitment to addressing unmet medical needs and its focus on scientific innovation and patient advocacy contribute positively to its reputation. Alnylam unveiled its five-year "Alnylam 2030" strategy, emphasizing leadership in ATTR amyloidosis, business scaling, and disciplined financial results, which has been met with positive sentiment from analysts.

Alnylam Pharmaceuticals, Inc. has a high level of institutional ownership, with 87.93% of shares held by institutions. Major institutional owners include Fmr Llc, Capital World Investors, Vanguard Group Inc, BlackRock, Inc., Capital Research Global Investors, and Jpmorgan Chase & Co. Individuals hold 0.42% of the shares, and insider ownership stands at 0.46%.